CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients

Ítems similars

• JAK2(V617F) myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML
  per: Dagher, Tracy, et al.
  Publicat: (2020)
• Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses
  per: Debureaux, Pierre-Edouard, et al.
  Publicat: (2020)
• Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms
  per: Barcelos, Michelle Maccarini, et al.
  Publicat: (2011)
• Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
  per: Hassan, Abdulaziz, et al.
  Publicat: (2015)
• GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms
  per: Yang, Naery, et al.
  Publicat: (2018)